Table 1 Characteristics of included studies in the network of evidence
Study | Restriction | Interventions | N |
|---|---|---|---|
Aerts et al. (2013) [49] (NVALT-10) | Nonsquamous histology | Erlotinib (150 mg) | 73 |
Erlotinib (150 mg) + pemetrexed (500 mg/m2) | 82 | ||
Aerts et al. (2013) [49] (NVALT-10) | Squamous histology | Erlotinib (150 mg) | 42 |
Docetaxel (75 mg/m2) + erlotinib (150 mg) | 34 | ||
Auliac et al. (2014) [50] | EGFR mutation negative or unknown | Docetaxel (75 mg/m2) | 74 |
Docetaxel (75 mg/m2) + erlotinib (150 mg) | 73 | ||
Borghaei et al. (2015) [39] (CheckMate 057) | Not restricted | Docetaxel (75 mg/m2) | 224 |
Nivolumab 3 mg/kg | 231 | ||
Brahmer et al. (2015)e [40] (CheckMate 017) | Not restricted | Docetaxel (75 mg/m2) | 108 |
Nivolumab 3 mg/kg | 117 | ||
Camps et al. (2006) [51] | Not restricted | Docetaxel (75 mg/m2) | 129 |
Frequent low-dose docetaxel | 125 | ||
Fossella (2000) [52] | Not restricted | Docetaxel (75 mg/m2) | 125 |
Docetaxel (100 mg/m2) | 125 | ||
Garassino et al. (2013) [53] (TAILOR) | EGFR mutation negative | Docetaxel (75 mg/m2) | 110 |
Erlotinib 150 mg | 109 | ||
Garon et al. (2014) [54] (REVEL) | Not restricted | Docetaxel (75 mg/m2) | 618 |
Docetaxel (75 mg/m2) + ramucirumab (10 mg/kg) | 622 | ||
Gervais et al. (2005) [55] | Not restricted | Docetaxel (75 mg/m2) | 62 |
Frequent low-dose docetaxel | 63 | ||
Gridelli et al. (2004) [56] (DISTAL 01) | Not restricted | Docetaxel (75 mg/m2) | 110 |
Frequent low-dose docetaxel | 110 | ||
Han et al. (2011) [57] | Not restricted | Docetaxel (75 mg/m2) | 40 |
Pemetrexed (500 mg/m2) | 44 | ||
Not restricted | Docetaxel (75 mg/m2) | 288 | |
Pemetrexed (500 mg/m2) | 283 | ||
Hanna et al. (2013) [59] (LUME-Lung 2) | Not restricted | Pemetrexed (500 mg/m2) | 360 |
Pemetrexed (500 mg/m2) + nintedanib (200 mg) | 353 | ||
Hosomi et al. (2015) [60] | Asian population | Docetaxel (60 mg/m2) | 81 |
Docetaxel (60 mg/m2) + ramucirumab (10 mg/kg) | 76 | ||
Juan et al. (2015) [61] | Not restricted | Erlotinib (150 mg) | 35 |
Docetaxel (75 mg/m2) + erlotinib (150 mg) | 33 | ||
Karampeazis et al. (2013) [62] (NCT00440414) | Not restricted | Erlotinib (150 mg) | 39 |
Pemetrexed (500 mg/m2) | 36 | ||
Asian population | Erlotinib (150 mg) | 252 | |
Gefitinib (250 mg) | 250 | ||
Kawaguchi et al. (2014) [46] (DELTA) | Asian population | Erlotinib (150 mg) | 150 |
Docetaxel (60 mg/m2) | 151 | ||
Kim et al. (2008) [64] | Not restricted | Docetaxel (75 mg/m2) | 710 |
Gefitinib (250 mg) | 723 | ||
Kim et al. (2014) [65] | Asian population | Pemetrexed (500 mg/m2) | 45 |
Gefitinib (250 mg) | 43 | ||
Lee et al. (2013) [66] | Not restricted | Erlotinib (150 mg) | 82 |
Pemetrexed (500 mg/m2) | 77 | ||
Erlotinib (150 mg) + pemetrexed (500 mg/m2) | 75 | ||
Nishino et al. (2015) [67] | Nonsquamous histology Asian population | Docetaxel (60 mg/m2) + bevacizumab (15 mg/kg) | 45 |
S-1 (40 mg/m2) + bevacizumab (15 mg/kg) | 45 | ||
Quoix et al. (2004) [68] | Not restricted | Docetaxel (75 mg/m2) | 93 |
Docetaxel (100 mg/m2) | 89 | ||
Reck et al. (2014) [38] (LUME-Lung 1) | Not restricted | Docetaxel (75 mg/m2) | 615 |
Docetaxel (75 mg/m2) + nintedanib (200 mg) | 598 | ||
Schuette et al. (2005) [69] | Not restricted | Docetaxel (75 mg/m2) | 103 |
Frequent low-dose docetaxel | 105 | ||
Shepherd et al. (2000) [70] | Not restricted | Docetaxel (75 mg/m2) | 55 |
Best supportive care | 49 | ||
Sun et al. (2012) [34] (KCSG-LU08–01) | Adenocarcinoma histology Asian population | Pemetrexed (500 mg/m2) | 67 |
Gefitinib (250 mg) | 68 | ||
Sun et al. (2013) [71] (JMID) | Asian population | Docetaxel (75 mg/m2) | 98 |
Pemetrexed (500 mg/m2) | 104 | ||
Nonsquamous histology Progressed after treatment with bevacizumab plus a platinum-based doublet. Asian population | Docetaxel (60 mg/m2) | 50 | |
Docetaxel (60 mg/m2) + bevacizumab (15 mg/kg) | 50 | ||
Nonsquamous histology EGFR mutation negative Asian population | Pemetrexed (500 mg/m2) | 76 | |
Gefitinib (250 mg) | 81 |